HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bacitracin A

cyclic dodecapeptide antibiotic from Bacillus licheniformis; structure in Merck Index, 9th ed, #942

Networked: 16 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Bacitracin: 483
      - bacitracin A: 16
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Bacitracin: 483
      - bacitracin A: 16

Experts

1.	Hong, Wei: 4 articles (03/2019 - 01/2018)
2.	Liu, Lipeng: 4 articles (03/2019 - 01/2018)
3.	Liu, Mingchun: 4 articles (03/2019 - 01/2018)
4.	Zhang, Dexian: 4 articles (03/2019 - 01/2018)
5.	Zhao, Yining: 4 articles (03/2019 - 01/2018)
6.	Liu, Yinghui: 2 articles (03/2019 - 09/2018)
7.	Zhang, Zehui: 2 articles (11/2018 - 01/2018)
8.	Aguilera, Mònica: 1 article (08/2021)
9.	Cryan, John F: 1 article (08/2021)
10.	Fanning, Aine: 1 article (08/2021)

Related Diseases

1.	Pneumonia (Pneumonitis) 01/01/2018 - "pneumonia was naturally resistant to its unassembled counterpart bacitracin A (BA). " 01/01/2022 - "Erratum: Insights into the Antibacterial Mechanism of PEGylated Nano-Bacitracin A Against Streptococcus pneumonia: Both Penicillin-Sensitive and Penicillin-Resistant Strains [Corrigendum]." 01/01/2019 - "Erratum: Insights into the antibacterial mechanism of PEGylated nano-bacitracin A against Streptococcus pneumonia: both penicillin-sensitive and penicillin-resistant strains [Corrigendum]." 01/01/2018 - "Insights into the antibacterial mechanism of PEGylated nano-bacitracin A against Streptococcus pneumonia: both penicillin-sensitive and penicillin-resistant strains."
2.	Peritonitis 03/06/2019 - "Correction to: Pluronic‑based nano‑self‑assemblies of bacitracin A with a new mechanism of action for an efficient in vivo therapeutic effect against bacterial peritonitis." 09/13/2022 - "Retraction Note To: Pluronic-based nano-self-assemblies of bacitracin A with a new mechanism of action for an efficient in vivo therapeutic effect against bacterial peritonitis." 09/11/2018 - "Pluronic-based nano-self-assemblies of bacitracin A with a new mechanism of action for an efficient in vivo therapeutic effect against bacterial peritonitis."
3.	Visceral Pain 08/03/2021 - "Wild-type (WT) and caspase-1/11 deficient (Casp1 KO) mice were orally treated for 2 weeks with an antibiotic cocktail (Abx, Bacitracin A and Neomycin), followed by quantification of representative fecal commensals (by qPCR), cecal short chain fatty acids (by HPLC), pathways implicated in the gut-neuro-immune axis (by RT-qPCR, immunofluorescence staining, and flow cytometry) in addition to capsaicin-induced visceral pain responses. "
4.	Allergic Contact Dermatitis 12/01/2020 - "Bacitracin: A Causative Agent of Purpuric Allergic Contact Dermatitis."
5.	Bacteremia 06/01/2015 - "Oral Bacitracin: A Consideration for Suppression of Intestinal Vancomycin-Resistant Enterococci (VRE) and for VRE Bacteremia From an Apparent Gastrointestinal Tract Source."

Related Drugs and Biologics

1.	Penicillins (Penicillin)
2.	Anti-Bacterial Agents (Antibiotics)
3.	Therapeutic Uses
4.	Poloxamer (Poloxamer 407)
5.	Fluoroquinolones
6.	Caspase 1 (ICE Protease)
7.	Anti-Allergic Agents (Antiallergic Agents)
8.	Peptides (Polypeptides)
9.	Neomycin
10.	Volatile Fatty Acids